Our Company
About Us
About Xanamem
®
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
The Cortisol Hypothesis
Mechanism of Action
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Anxiety, sleep & behavioral problems in Fragile X Syndrome
Patient Portal
Participate in clinical trials
The XanaCIDD Depression Clinical Trial
The XanaMIA Phase 2b Alzheimer’s Trial
Publications
Investor Centre
Share Price
ASX Announcements
Corporate Presentations
Analyst Reports
Financial Results Centre
Annual General Meeting
General Meeting
Financial Calendar
Right to Receive Documents
Frequently Asked Questions
Investor Contacts
News
Contact Us
News
Latest Summary Corporate Presentation
November 2023
View Presentation
All updates and Media
Media
Corporate Presentations
18 Oct 2023
Actinogen
Latest Summary Corporate Presentation October 2023
06 Oct 2023
Actinogen
Company Presentation: ACW CEO presents to Dementia Trials Australia conference
29 Sep 2023
Actinogen
Company Presentation: ACW Clinical Scientist presents to the Asian Society Against Dementia congress
14 Sep 2023
Actinogen
Video interview: [14.46 mins] Xanamem program update
31 Aug 2023
Media
Webcast video recording: Actinogen neuroscience webinar
07 Jun 2023
PR Newswire
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023
PR Newswire
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
31 May 2023
Yahoo Finance
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
24 May 2023
Actinogen
Webcast video recording: Actinogen Clinical Trials Science Forum 2023
30 Mar 2023
PR Newswire
Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
30 Mar 2023
Actinogen
Oral presentation: CMO presentation at Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) in Gothenburg, Sweden
01 Mar 2023
Biotech Daily
Actinogen Appoints Nicki Vasquez Non-Executive Director
24 Feb 2023
Actinogen
Company presentation: Spark Plus Biotech Conference in Singapore
01 Feb 2023
Biotech Daily
Actinogen Appoints Dr Dana Hilt CMO
09 Jan 2023
Actinogen
Company presentation: Sachs Neuroscience Innovation Forum and other meetings during the JP Morgan Healthcare Conference week
22 Dec 2022
Biotech Daily
FDA Okays Actinogen 6-Months Xanamem Phase IIb Alzheimer’s Trial
22 Dec 2022
Seeking Alpha
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022
PR Newswire
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022
MarketWatch
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022
Yahoo
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
22 Dec 2022
The Market Herald
Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial
22 Dec 2022
BioSpace
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
15 Dec 2022
Yahoo Finance
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022
Daily Bulletin
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
15 Dec 2022
BioPharma APAC
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022
PR Newswire
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
14 Dec 2022
BioSpace
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
08 Dec 2022
Biotech Daily
Actinogen Treats First Xanamem Depression Patient
03 Dec 2022
Actinogen
Poster presentation: CTAD conference 2022
25 Nov 2022
Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
16 Nov 2022
Actinogen
Webcast video recording: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
16 Nov 2022
Actinogen
Company presentation: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
09 Nov 2022
Bell Potter
Webcast video recording: CEO presentation to Bell Potter Healthcare Conference 2022
09 Nov 2022
Actinogen
Company presentation: CEO presentation to Bell Potter Healthcare Conference 2022
03 Nov 2022
SparkPlus
Webinar video recording: CEO presentation at Spark Plus Healthcare Day
03 Nov 2022
Actinogen
Company presentation: CEO presentation to Spark Plus Healthcare Day
24 Oct 2022
ShareCafe
Webinar video recording: CEO presentation at ShareCafe “Hidden Gems”
21 Oct 2022
Yahoo Finance
Actinogen Medical: re-initiation — Cognitive enhancer targeting key diseases
21 Oct 2022
Actinogen
Company presentation: CEO presentation at ShareCafe “Hidden Gems”
19 Oct 2022
Stockhead
Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
19 Oct 2022
FN Arena
Australian Broker Call *Extra* Edition – Oct 19, 2022
12 Oct 2022
Outsourcing-Pharma.com
“Significant Step Forward” for Actinogen’s Alzheimer’s treatment
11 Oct 2022
EIN Presswire
Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
11 Oct 2022
BioWorld
Biomarker analysis yields clinical benefit for Actinogen’s Xanamem in Alzheimer’s disease
10 Oct 2022
Actinogen
Webcast video recording: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022
The Market Herald
Actinogen Medical (ASX:ACW) finds positive results in phase 2A trial of Xanamem on Alzheimers
10 Oct 2022
BioSpace
Clinical Catch-Up: Actinogen, Applied Therapeutics, BrainStorm, Immatics, and More
10 Oct 2022
Labiotech.eu
Positive data indicates likely therapeutic effect of Alzheimer’s drug
10 Oct 2022
Biotech Daily
Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022
The Motley Fool
Why Actinogen, Core Lithium, Fortescue, and Galileo Mining shares are pushing higher
Load more
Back
to top